查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1803583

全球地塞米松植入市场（按适应症、剂型、材料类型、交付途径、最终用户和患者类型）：预测（2025-2030 年）

Dexamethasone Implant Market by Indication, Dosage Form, Material Type, Delivery Route, End Users, Patient Type - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 181 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2024 年地塞米松植入市值为 4.9514 亿美元，预计到 2025 年将成长至 5.3099 亿美元，复合年增长率为 7.50%，到 2030 年将达到 7.6457 亿美元。

主要市场统计数据
预测年份（2024年） 4.9514亿美元
基准年（2025年） 5.3099亿美元
预测年份（2030年） 7.6457亿美元
复合年增长率（%） 7.50%

全面介绍地塞米松植入市场格局，重点在于临床相关性、市场格局和分析目标

眼科治疗的进展凸显了缓释性类固醇植入在治疗眼后节慢性发炎性疾病的重要性。过去十年，地塞米松植入已成为视网膜疾病治疗通讯协定的基石，它透过可控的药物传递减轻了频繁玻璃体内注射的负担。随着人口结构变化和糖尿病的流行，视力障碍的发生率持续上升，了解地塞米松植入的临床意义和战略机会变得前所未有的紧迫。

分析技术进步、以病人为中心的创新和监管变革对地塞米松植入市场的影响

生物生物分解性聚合物和精密製造技术的进步从根本上改变了眼部药物传递的轨迹。缓释性如今利用聚乳酸-乙醇酸共聚物和聚己内酯等突破性技术来控製药物动力学、增强疗效并减少注射频率。同时，各大地区的监管机构也日益支持这些创新，简化核准流程，并引进新的上市后监管架构。

国际贸易动态以及 2025 年美国关税对地塞米松植入供应链、定价和相关人员策略的累积影响

2025年美国新关税的实施，加剧了地塞米松植入供应链的复杂性。关键生物分解性聚合物的原料成本面临上涨压力，迫使製造商重新评估筹资策略，并与供应商协商成本分摊协议。这些发展趋势也影响着分销网络内多个接触点的定价结构，付款人和医疗保健提供者都要求更透明且可证明的价值。

详细的細項分析显示，适应症、剂型、材料类型、给药途径、最终用户和患者人口统计数据推动了市场差异化

根据适应症对地塞米松植入空间进行细分，可以揭示黄斑部水肿、非感染性葡萄膜炎和术后发炎中不同的生长载体。在黄斑部水肿患者群中，糖尿病黄斑部水肿和视网膜静脉阻塞代表着独特的患者路径，需要客製化的释放曲线和给药方案。同时，非感染性葡萄膜炎受益于持续性皮质类固醇给药，可减轻发炎復发负担并改善长期视力结果。术后发炎管理越来越多地利用植入技术，这些技术可在白内障和玻璃体视网膜手术后提供可预测的抗发炎益处。

全面的区域洞察，重点关注美洲、中东和非洲以及亚太市场的独特动态和驱动力

在美洲，完善的医疗基础设施和先进的支付机制支持地塞米松植入的快速普及，尤其是在大型眼科中心。该地区强大的临床试验管道和明确的报销代码为植入创新创造了成熟的环境。另一方面，拉丁美洲经济体也提供了成长空间，医疗支出的增加和手术能力的提升正在扩大患者获得治疗的管道。

策略公司概况和竞争格局为塑造地塞米松植入开发和分销未来的关键创新者提供了重要见解

领先的製药和医疗设备公司正透过对研发、生产和伙伴关係生态系统的策略性投资，加强对地塞米松植入平台的关注。全球公司正透过将其独特的聚合物科学能力与眼科专业知识相结合，扩大产品系列併提升竞争地位。与委外研发机构和学术中心共同开发契约正在加速下一代製剂的共同开发，确保强有力的智慧财产权保护和简化的监管途径。

指导产业领导者克服监管挑战、促进创新、优化供应链和加强市场定位的可行建议

为了应对错综复杂的监管障碍和竞争压力，行业领导者应优先考虑与监管机构的早期沟通。建立积极的沟通管道可以加快核准速度，并明确上市后的承诺。此外，投资先进的生物相容性材料和智慧传输技术，可以使植入产品组合更具差异化，并满足临床医生对精准药物释放日益增长的期望。

全面的调查方法，涵盖资料来源、分析框架、检验流程和统计方法，以支持市场研究

本分析采用了混合方法研究设计，结合了一手资料和二手资料。一手资料研究包括对视网膜专家、监管事务专业人员和供应链高管的深入访谈，以了解第一线人员对临床表现、核准流程和物流复杂性的观点。二手资料研究则提取自同行评审日誌、监管申请、专利资料库和会议论文集，以建立全面的依证。

一个富有洞察力的结论，总结了地塞米松植入生态系统相关人员的关键发现、战略意义和未来前景

综上所述，主要研究结果表明，地塞米松植入在缓释性给药和先进眼科治疗的交叉领域中占据着重要的地位。突破性的材料创新和以患者为中心的护理模式正在融合，推动其广泛应用，而关税方面的不利因素则要求制定灵活的供应链策略。細項分析突显了其临床应用的广度，以及根据个别患者情况客製化剂量、材料和给药方案的需求。

目录

第一章 引言

第二章 分析方法

第三章执行摘要

第四章 市场概述

第五章市场动态

  • 临床指引的变化导致地塞米松植入在视网膜静脉阻塞治疗中的仿单标示外使用量增加。
  • 生物分解性聚合物技术进展改善玻璃体内地塞米松植入的缓释特性
  • 地塞米松植入在糖尿病黄斑部水肿治疗的应用日益广泛，这是基于现实世界的疗效证据
  • 增加对地塞米松植入与抗 VEGF 药物联合治疗的投资，以协同控制视网膜疾病
  • 随着生物相似药地塞米松植入进入主要市场，竞争格局发生变化，对现有产品独占性构成挑战
  • 基于人工智慧的病患反应监测平台实现地塞米松植入的新兴个人化给药通讯协定

第六章 市场洞察

  • 波特五力分析
  • PESTEL分析

第七章：美国关税的累积影响（2025年）

8. 地塞米松植入市场（按适应症）

  • 黄斑部水肿
    • 糖尿病黄斑部水肿（DME）
    • 视网膜静脉阻塞（RVO）
  • 非感染性葡萄膜炎
  • 术后炎症

9. 地塞米松植入市场（按剂型）

  • 0.35毫克植入
  • 0.7毫克植入

第十章地塞米松植入市场（依材料类型）

  • 聚（乳酸-乙醇酸）(PLGA)
  • 聚己内酯（PCL）

11. 地塞米松植入市场（依给药途径）

  • 玻璃体内
  • 结膜下

第 12 章 地塞米松植入市场（依最终用户）

  • 学术研究机构
  • 门诊手术中心
  • 医院
  • 眼科诊所

13. 地塞米松植入市场（依病患类型）

  • 成人
  • 老年人
  • 孩子们

14.美洲地塞米松植入市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 阿根廷

15. 欧洲、中东和非洲地塞米松植入市场

  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 阿拉伯聯合大公国
  • 沙乌地阿拉伯
  • 南非
  • 丹麦
  • 荷兰
  • 卡达
  • 芬兰
  • 瑞典
  • 奈及利亚
  • 埃及
  • 土耳其
  • 以色列
  • 挪威
  • 波兰
  • 瑞士

16. 亚太地塞米松植入市场

  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国
  • 印尼
  • 泰国
  • 菲律宾
  • 马来西亚
  • 新加坡
  • 越南
  • 台湾

第十七章竞争格局

  • 市场占有率分析（2024年）
  • FPNV定位矩阵（2024年）
  • 竞争情境分析
    • AbbVie Inc.
    • 3S Corporation
    • Santen Pharmaceutical Co., Ltd.
    • GNH India Pharmaceuticals Limited.
    • Mehan Healthcare Private Limited.

第十八章 研究人工智慧

第十九章 研究统计

第二十章 研究联络人

第21章 研究报导

第22章 附录

Product Code: MRR-537DB9F46DC6

The Dexamethasone Implant Market was valued at USD 495.14 million in 2024 and is projected to grow to USD 530.99 million in 2025, with a CAGR of 7.50%, reaching USD 764.57 million by 2030.

KEY MARKET STATISTICS
Base Year [2024] USD 495.14 million
Estimated Year [2025] USD 530.99 million
Forecast Year [2030] USD 764.57 million
CAGR (%) 7.50%

Comprehensive Introduction to the Dexamethasone Implant Landscape Emphasizing Clinical Relevance, Market Context and Analysis Objectives

The evolution of ocular therapeutics has underscored the significance of sustained-release steroid implants in addressing chronic inflammatory conditions of the posterior segment. Over the past decade, dexamethasone implants have emerged as a cornerstone of treatment protocols for retinal disorders, offering controlled drug delivery that mitigates the burdens of frequent intravitreal injections. As demographic shifts and the prevalence of diabetes continue to intensify the incidence of visual impairment, understanding the clinical implications and strategic opportunities surrounding dexamethasone implants has never been more urgent.

This executive overview sets forth the foundational context for evaluating the therapeutic, regulatory, and commercial dimensions of dexamethasone intravitreal implants. By outlining the clinical rationale for sustained-release corticosteroid delivery, this introduction positions stakeholders to appreciate the nuanced interplay between emerging material sciences, delivery modalities, and patient adherence considerations. It also delineates the overarching goals of the analysis: to inform strategic planning, guide resource allocation, and illuminate pathways for innovation.

In highlighting the scope of this research, emphasis is placed on synthesizing current scientific consensus, regulatory developments, and competitive intelligence. This initial section anchors the reader in the critical drivers of the dexamethasone implant market and establishes the framework for subsequent sections that will explore transformative shifts, tariff impacts, segmentation insights, regional dynamics, corporate strategies, and actionable recommendations.

Analysis of Transformative Shifts Reshaping the Dexamethasone Implant Market Through Technological Advances, Patient-Centric Innovations, and Regulatory Evolutions

Advances in biodegradable polymers and precision manufacturing have fundamentally altered the trajectory of ocular drug delivery. Sustained-release formulations now leverage breakthroughs in poly(lactic-co-glycolic acid) and polycaprolactone technologies to orchestrate controlled pharmacokinetics, elevating therapeutic efficacy and reducing injection frequency. Concurrently, regulatory agencies across major territories have increasingly endorsed these innovations, streamlining approval timelines while introducing novel post-marketing surveillance frameworks.

Patient engagement platforms and digital imaging tools have likewise catalyzed a shift toward patient-centric care models, enabling real-time monitoring of implant performance and adverse events. These developments align with a broader healthcare ecosystem that prioritizes value-based outcomes and evidence-driven reimbursement. As integrated diagnostics become more prevalent, ophthalmologists and retina specialists are equipped to tailor interventions based on predictive biomarkers, further enhancing the clinical utility of dexamethasone implants.

In response to these converging trends, manufacturers are forging collaborations with medical technology firms and academic research centers. Such alliances drive iterative improvements in implant design, enhance biocompatibility, and foster the integration of smart delivery systems. Consequently, the dexamethasone implant sector is undergoing a transformative recalibration that extends beyond product innovation to encompass regulatory strategy, patient engagement, and cross-sector partnerships.

International Trade Dynamics and the Cumulative Impact of 2025 United States Tariffs on Dexamethasone Implant Supply Chains, Pricing, and Stakeholder Strategies

The implementation of new United States tariff measures in 2025 has introduced a layer of complexity across the dexamethasone implant supply chain. Raw material costs for key biodegradable polymers have experienced upward pressure, prompting manufacturers to reassess sourcing strategies and negotiate cost-sharing agreements with suppliers. These dynamics have, in turn, influenced pricing structures at multiple junctures within the distribution network, with payers and providers demanding greater transparency and demonstrable value.

Moreover, the tariff environment has underscored the importance of regional manufacturing hubs in mitigating exposure to cross-border levies. Several leading implant producers have accelerated investment in domestic production capacity, leveraging advanced polymer processing facilities to secure supply security. At the same time, alternative routes for polymer synthesis and localized partnerships with contract development and manufacturing organizations have emerged as viable strategies to insulate margins.

Stakeholders must also navigate evolving customs protocols and compliance requirements, which now feature enhanced reporting obligations and risk assessments for medical devices. In response, industry participants are reinforcing their regulatory affairs teams and deploying digital trade management platforms to streamline tariff classification and duty mitigation. Through these collective efforts, companies can preserve innovation incentives while maintaining competitive positioning in a tariff-impacted landscape.

In-Depth Segment Analysis Revealing How Indication, Dosage Form, Material Type, Delivery Route, End Users, and Patient Demographics Drive Market Differentiation

Segmenting the dexamethasone implant arena by indication reveals differentiated growth vectors across macular edema, non-infectious uveitis, and post-operative inflammation. Within the macular edema cohort, diabetic macular edema and retinal vein occlusion present unique patient pathways, each demanding tailored release profiles and dosing regimens. Meanwhile, the non-infectious uveitis segment benefits from sustained corticosteroid coverage, reducing the burden of recurrent inflammation and improving long-term visual outcomes. Post-operative inflammation management further leverages implant technology to deliver predictable anti-inflammatory effects following cataract or vitreoretinal surgeries.

Dosage form variations, namely 0.35 milligram and 0.7 milligram implants, allow clinicians to align therapy intensity with disease severity and patient tolerance. Lower-dose implants offer a favorable safety profile for mild to moderate cases, whereas higher-dose configurations are preferred when robust, extended-release activity is required. Material composition also plays a pivotal role; poly(lactic-co-glycolic acid) formulations enable rapid polymer breakdown and drug release, while polycaprolactone matrices afford slower degradation and prolonged therapeutic exposure.

Delivery route options add another dimension of customization, with intravitreal administration remaining the standard of care but emerging interest in subconjunctival approaches for anterior segment applications. End-user preferences within academic research institutes, ambulatory surgical centers, hospitals, and ophthalmic clinics shape adoption curves and influence training priorities. Patient demographics-across adult, geriatric, and pediatric groups-further dictate tolerability assessments and inform the development of pediatric-friendly implant variants. Collectively, these segmentation insights illuminate the multifaceted decision drivers that underpin product differentiation and clinical adoption.

Comprehensive Regional Insights Highlighting the Unique Dynamics and Growth Drivers Across the Americas, Europe Middle East & Africa, and Asia-Pacific Markets

In the Americas, established healthcare infrastructures and advanced payment mechanisms support rapid uptake of dexamethasone implants, particularly within leading ophthalmology centers. The region's robust pipeline of clinical trials and well-defined reimbursement codes underpin a mature environment for implant innovations. Conversely, economies within Latin America present pockets of growth, where rising healthcare expenditure and expanding surgical capacity are broadening patient access.

Within Europe, Middle East & Africa, variances in regulatory frameworks and reimbursement pathways create a mosaic of market conditions. Western European countries, bolstered by centralized approval processes and coordinated pricing negotiations, serve as early adopters of next-generation biodegradable implants. In contrast, emerging markets in the Middle East and parts of Africa are characterized by nascent clinical infrastructure and evolving procurement protocols, presenting both challenges and opportunities for tailored market entry strategies.

Asia-Pacific exhibits dynamic expansion driven by demographic trends, increasing incidence of diabetic complications, and government initiatives to strengthen ophthalmic care. Rapidly developing healthcare sectors in China and India are prioritizing capacity building in retinal services, while mature markets like Japan maintain rigorous regulatory standards that align closely with global best practices. These regional variances underscore the imperative for localized engagement models and flexible commercialization plans.

Strategic Company Profiles and Competitive Landscapes Offering Critical Insights into Leading Innovators Shaping the Future of Dexamethasone Implant Development and Distribution

Leading pharmaceutical and medical device companies are intensifying their focus on dexamethasone implant platforms through strategic investments in research, manufacturing, and partnership ecosystems. Global players have expanded their product portfolios by integrating proprietary polymer science capabilities with ophthalmology expertise, thereby enhancing their competitive moats. Collaboration agreements with contract development organizations and academic centers have accelerated the co-development of next-generation formulations, ensuring robust intellectual property protection and streamlined regulatory pathways.

Mid-sized and specialized biotech firms are carving out niches by capitalizing on novel delivery modalities and patient engagement technologies. These entities often pursue licensing deals and distribution partnerships to extend their geographic reach and access complementary channels. Meanwhile, established implant manufacturers are reinforcing their global distribution networks, optimizing cold-chain logistics, and deploying digital platforms to facilitate order management and end-to-end traceability.

Across the competitive landscape, a recurring emphasis on lifecycle management strategies reflects the drive to differentiate through incremental formulation tweaks and novel dosage strengths. These approaches are supported by real-world evidence studies and post-market surveillance initiatives that quantify long-term safety and adherence benefits. Through these collective efforts, key companies are shaping the future trajectory of dexamethasone implant innovation and commercialization.

Actionable Recommendations to Guide Industry Leaders Through Regulatory Challenges, Foster Innovation, Optimize Supply Chains, and Strengthen Market Positioning

To navigate the complex interplay of regulatory hurdles and competitive pressures, industry leaders should prioritize early engagement with regulatory authorities. Establishing proactive communication channels can expedite approval timelines and clarify evolving post-marketing commitments. Further, investing in advanced biocompatible materials and smart delivery technologies will differentiate implant portfolios and meet rising clinician expectations for precision drug release.

Optimizing supply chain resilience demands diversification of raw material sources and the establishment of regional manufacturing footprints. Embracing strategic partnerships with contract manufacturers in key geographies can mitigate tariff exposure and enhance production flexibility. Simultaneously, integrating digital trade management platforms will streamline compliance and reduce administrative risk.

Finally, engaging patients and providers through tailored educational programs and digital adherence tools will reinforce value propositions and drive favorable reimbursement negotiations. By leveraging real-world outcomes data and patient-reported experience metrics, companies can underscore the clinical and economic benefits of sustained-release dexamethasone implants, thereby reinforcing their standing within formulary discussions and treatment guidelines.

Comprehensive Research Methodology Covering Data Sources, Analytical Frameworks, Validation Processes, and Statistical Techniques Supporting the Market Study

This analysis employed a mixed-methods research design combining primary and secondary data sources. Primary insights were obtained through in-depth interviews with retina specialists, regulatory affairs experts, and supply chain executives to capture frontline perspectives on clinical performance, approval processes, and logistical complexities. Secondary research drew from peer-reviewed journals, regulatory filings, patent databases, and conference proceedings to construct a comprehensive evidence base.

Data triangulation techniques were applied to validate qualitative findings against quantitative indicators, ensuring consistency and reliability. Key variables such as polymer degradation rates, dosage efficacy benchmarks, and price trend analyses were subjected to sensitivity testing to highlight scenario-based impacts. Ethical standards and data integrity protocols were strictly observed, with all proprietary sources anonymized to maintain confidentiality.

Analytical frameworks incorporated SWOT assessments, competitive benchmarking, and PESTEL analysis to contextualize market drivers and barriers. Advanced statistical tools were leveraged for trend analysis, while visual dashboards facilitated clear interpretation of complex datasets. This rigorous methodology underpins the credibility of the strategic insights and recommendations presented herein.

Insightful Conclusion Summarizing Key Findings, Strategic Implications, and Future Outlook for Stakeholders in the Dexamethasone Implant Ecosystem

In synthesizing the key findings, it is evident that dexamethasone implants occupy a critical niche at the intersection of sustained-release drug delivery and advanced ophthalmic therapy. Transformative material innovations and patient-centric care models are coalescing to drive adoption, even as tariff headwinds necessitate agile supply chain strategies. The segmentation analysis underscores the breadth of clinical applications and the need for tailored dosing, material, and delivery options to address distinct patient profiles.

Regional dynamics reveal the importance of localized regulatory and reimbursement engagements, with each geography presenting unique enablers and constraints. Competitive landscapes are marked by strategic alliances and lifecycle management initiatives, reflecting the high stakes of capturing value in this evolving space. Accordingly, industry participants must align their R&D investments, manufacturing footprints, and commercial approaches with these multifaceted imperatives.

Looking ahead, the convergence of real-world evidence, digital health integrations, and advanced polymer science will define the next frontier of dexamethasone implant innovation. Stakeholders who proactively embrace these themes will be best positioned to shape clinical practice, secure favorable policy outcomes, and drive long-term growth in this vital segment of ophthalmic care.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Market Sizing & Forecasting

5. Market Dynamics

  • 5.1. Growing off-label applications for dexamethasone implants in retinal vein occlusion management due to shifting clinical guidelines
  • 5.2. Advances in biodegradable polymer technologies improving sustained-release profiles of dexamethasone intravitreal implants
  • 5.3. Increasing adoption of dexamethasone implant in diabetic macular edema treatment driven by real-world evidence of efficacy
  • 5.4. Rising investment in combination therapies integrating dexamethasone implants with anti-VEGF agents for synergistic retinal disease control
  • 5.5. Competitive landscape shift as biosimilar dexamethasone implants enter key markets challenging established product exclusivity
  • 5.6. Emergence of personalized dosing protocols for dexamethasone implants enabled by AI-based patient response monitoring platforms

6. Market Insights

  • 6.1. Porter's Five Forces Analysis
  • 6.2. PESTLE Analysis

7. Cumulative Impact of United States Tariffs 2025

8. Dexamethasone Implant Market, by Indication

  • 8.1. Introduction
  • 8.2. Macular Edema
    • 8.2.1. Diabetic Macular Edema (DME)
    • 8.2.2. Retinal Vein Occlusion (RVO)
  • 8.3. Non-Infectious Uveitis
  • 8.4. Post-Operative Inflammation

9. Dexamethasone Implant Market, by Dosage Form

  • 9.1. Introduction
  • 9.2. 0.35 mg Implants
  • 9.3. 0.7 mg Implants

10. Dexamethasone Implant Market, by Material Type

  • 10.1. Introduction
  • 10.2. Poly(lactic-co-glycolic acid) (PLGA)
  • 10.3. Polycaprolactone (PCL)

11. Dexamethasone Implant Market, by Delivery Route

  • 11.1. Introduction
  • 11.2. Intravitreal
  • 11.3. Subconjunctival

12. Dexamethasone Implant Market, by End Users

  • 12.1. Introduction
  • 12.2. Academic & Research Institutes
  • 12.3. Ambulatory Surgical Centers
  • 12.4. Hospitals
  • 12.5. Ophthalmic Clinics

13. Dexamethasone Implant Market, by Patient Type

  • 13.1. Introduction
  • 13.2. Adult
  • 13.3. Geriatric
  • 13.4. Pediatric

14. Americas Dexamethasone Implant Market

  • 14.1. Introduction
  • 14.2. United States
  • 14.3. Canada
  • 14.4. Mexico
  • 14.5. Brazil
  • 14.6. Argentina

15. Europe, Middle East & Africa Dexamethasone Implant Market

  • 15.1. Introduction
  • 15.2. United Kingdom
  • 15.3. Germany
  • 15.4. France
  • 15.5. Russia
  • 15.6. Italy
  • 15.7. Spain
  • 15.8. United Arab Emirates
  • 15.9. Saudi Arabia
  • 15.10. South Africa
  • 15.11. Denmark
  • 15.12. Netherlands
  • 15.13. Qatar
  • 15.14. Finland
  • 15.15. Sweden
  • 15.16. Nigeria
  • 15.17. Egypt
  • 15.18. Turkey
  • 15.19. Israel
  • 15.20. Norway
  • 15.21. Poland
  • 15.22. Switzerland

16. Asia-Pacific Dexamethasone Implant Market

  • 16.1. Introduction
  • 16.2. China
  • 16.3. India
  • 16.4. Japan
  • 16.5. Australia
  • 16.6. South Korea
  • 16.7. Indonesia
  • 16.8. Thailand
  • 16.9. Philippines
  • 16.10. Malaysia
  • 16.11. Singapore
  • 16.12. Vietnam
  • 16.13. Taiwan

17. Competitive Landscape

  • 17.1. Market Share Analysis, 2024
  • 17.2. FPNV Positioning Matrix, 2024
  • 17.3. Competitive Analysis
    • 17.3.1. AbbVie Inc.
    • 17.3.2. 3S Corporation
    • 17.3.3. Santen Pharmaceutical Co., Ltd.
    • 17.3.4. GNH India Pharmaceuticals Limited.
    • 17.3.5. Mehan Healthcare Private Limited.

18. ResearchAI

19. ResearchStatistics

20. ResearchContacts

21. ResearchArticles

22. Appendix

LIST OF FIGURES

  • FIGURE 1. DEXAMETHASONE IMPLANT MARKET RESEARCH PROCESS
  • FIGURE 2. GLOBAL DEXAMETHASONE IMPLANT MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 3. GLOBAL DEXAMETHASONE IMPLANT MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 4. GLOBAL DEXAMETHASONE IMPLANT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL DEXAMETHASONE IMPLANT MARKET SIZE, BY INDICATION, 2024 VS 2030 (%)
  • FIGURE 6. GLOBAL DEXAMETHASONE IMPLANT MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL DEXAMETHASONE IMPLANT MARKET SIZE, BY DOSAGE FORM, 2024 VS 2030 (%)
  • FIGURE 8. GLOBAL DEXAMETHASONE IMPLANT MARKET SIZE, BY DOSAGE FORM, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL DEXAMETHASONE IMPLANT MARKET SIZE, BY MATERIAL TYPE, 2024 VS 2030 (%)
  • FIGURE 10. GLOBAL DEXAMETHASONE IMPLANT MARKET SIZE, BY MATERIAL TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL DEXAMETHASONE IMPLANT MARKET SIZE, BY DELIVERY ROUTE, 2024 VS 2030 (%)
  • FIGURE 12. GLOBAL DEXAMETHASONE IMPLANT MARKET SIZE, BY DELIVERY ROUTE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 13. GLOBAL DEXAMETHASONE IMPLANT MARKET SIZE, BY END USERS, 2024 VS 2030 (%)
  • FIGURE 14. GLOBAL DEXAMETHASONE IMPLANT MARKET SIZE, BY END USERS, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 15. GLOBAL DEXAMETHASONE IMPLANT MARKET SIZE, BY PATIENT TYPE, 2024 VS 2030 (%)
  • FIGURE 16. GLOBAL DEXAMETHASONE IMPLANT MARKET SIZE, BY PATIENT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 17. AMERICAS DEXAMETHASONE IMPLANT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 18. AMERICAS DEXAMETHASONE IMPLANT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 19. UNITED STATES DEXAMETHASONE IMPLANT MARKET SIZE, BY STATE, 2024 VS 2030 (%)
  • FIGURE 20. UNITED STATES DEXAMETHASONE IMPLANT MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA DEXAMETHASONE IMPLANT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA DEXAMETHASONE IMPLANT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 23. ASIA-PACIFIC DEXAMETHASONE IMPLANT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 24. ASIA-PACIFIC DEXAMETHASONE IMPLANT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 25. DEXAMETHASONE IMPLANT MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 26. DEXAMETHASONE IMPLANT MARKET, FPNV POSITIONING MATRIX, 2024
  • FIGURE 27. DEXAMETHASONE IMPLANT MARKET: RESEARCHAI
  • FIGURE 28. DEXAMETHASONE IMPLANT MARKET: RESEARCHSTATISTICS
  • FIGURE 29. DEXAMETHASONE IMPLANT MARKET: RESEARCHCONTACTS
  • FIGURE 30. DEXAMETHASONE IMPLANT MARKET: RESEARCHARTICLES

LIST OF TABLES

  • TABLE 1. DEXAMETHASONE IMPLANT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL DEXAMETHASONE IMPLANT MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL DEXAMETHASONE IMPLANT MARKET SIZE, 2025-2030 (USD MILLION)
  • TABLE 5. GLOBAL DEXAMETHASONE IMPLANT MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL DEXAMETHASONE IMPLANT MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 7. GLOBAL DEXAMETHASONE IMPLANT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL DEXAMETHASONE IMPLANT MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 9. GLOBAL DEXAMETHASONE IMPLANT MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL DEXAMETHASONE IMPLANT MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
  • TABLE 11. GLOBAL DEXAMETHASONE IMPLANT MARKET SIZE, BY MACULAR EDEMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL DEXAMETHASONE IMPLANT MARKET SIZE, BY MACULAR EDEMA, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 13. GLOBAL DEXAMETHASONE IMPLANT MARKET SIZE, BY DIABETIC MACULAR EDEMA (DME), BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL DEXAMETHASONE IMPLANT MARKET SIZE, BY DIABETIC MACULAR EDEMA (DME), BY REGION, 2025-2030 (USD MILLION)
  • TABLE 15. GLOBAL DEXAMETHASONE IMPLANT MARKET SIZE, BY RETINAL VEIN OCCLUSION (RVO), BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL DEXAMETHASONE IMPLANT MARKET SIZE, BY RETINAL VEIN OCCLUSION (RVO), BY REGION, 2025-2030 (USD MILLION)
  • TABLE 17. GLOBAL DEXAMETHASONE IMPLANT MARKET SIZE, BY MACULAR EDEMA, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL DEXAMETHASONE IMPLANT MARKET SIZE, BY MACULAR EDEMA, 2025-2030 (USD MILLION)
  • TABLE 19. GLOBAL DEXAMETHASONE IMPLANT MARKET SIZE, BY NON-INFECTIOUS UVEITIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL DEXAMETHASONE IMPLANT MARKET SIZE, BY NON-INFECTIOUS UVEITIS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 21. GLOBAL DEXAMETHASONE IMPLANT MARKET SIZE, BY POST-OPERATIVE INFLAMMATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL DEXAMETHASONE IMPLANT MARKET SIZE, BY POST-OPERATIVE INFLAMMATION, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 23. GLOBAL DEXAMETHASONE IMPLANT MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL DEXAMETHASONE IMPLANT MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
  • TABLE 25. GLOBAL DEXAMETHASONE IMPLANT MARKET SIZE, BY 0.35 MG IMPLANTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL DEXAMETHASONE IMPLANT MARKET SIZE, BY 0.35 MG IMPLANTS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 27. GLOBAL DEXAMETHASONE IMPLANT MARKET SIZE, BY 0.7 MG IMPLANTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL DEXAMETHASONE IMPLANT MARKET SIZE, BY 0.7 MG IMPLANTS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 29. GLOBAL DEXAMETHASONE IMPLANT MARKET SIZE, BY MATERIAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL DEXAMETHASONE IMPLANT MARKET SIZE, BY MATERIAL TYPE, 2025-2030 (USD MILLION)
  • TABLE 31. GLOBAL DEXAMETHASONE IMPLANT MARKET SIZE, BY POLY(LACTIC-CO-GLYCOLIC ACID) (PLGA), BY REGION, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL DEXAMETHASONE IMPLANT MARKET SIZE, BY POLY(LACTIC-CO-GLYCOLIC ACID) (PLGA), BY REGION, 2025-2030 (USD MILLION)
  • TABLE 33. GLOBAL DEXAMETHASONE IMPLANT MARKET SIZE, BY POLYCAPROLACTONE (PCL), BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL DEXAMETHASONE IMPLANT MARKET SIZE, BY POLYCAPROLACTONE (PCL), BY REGION, 2025-2030 (USD MILLION)
  • TABLE 35. GLOBAL DEXAMETHASONE IMPLANT MARKET SIZE, BY DELIVERY ROUTE, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL DEXAMETHASONE IMPLANT MARKET SIZE, BY DELIVERY ROUTE, 2025-2030 (USD MILLION)
  • TABLE 37. GLOBAL DEXAMETHASONE IMPLANT MARKET SIZE, BY INTRAVITREAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL DEXAMETHASONE IMPLANT MARKET SIZE, BY INTRAVITREAL, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 39. GLOBAL DEXAMETHASONE IMPLANT MARKET SIZE, BY SUBCONJUNCTIVAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL DEXAMETHASONE IMPLANT MARKET SIZE, BY SUBCONJUNCTIVAL, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 41. GLOBAL DEXAMETHASONE IMPLANT MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL DEXAMETHASONE IMPLANT MARKET SIZE, BY END USERS, 2025-2030 (USD MILLION)
  • TABLE 43. GLOBAL DEXAMETHASONE IMPLANT MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL DEXAMETHASONE IMPLANT MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 45. GLOBAL DEXAMETHASONE IMPLANT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL DEXAMETHASONE IMPLANT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 47. GLOBAL DEXAMETHASONE IMPLANT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL DEXAMETHASONE IMPLANT MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 49. GLOBAL DEXAMETHASONE IMPLANT MARKET SIZE, BY OPHTHALMIC CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL DEXAMETHASONE IMPLANT MARKET SIZE, BY OPHTHALMIC CLINICS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 51. GLOBAL DEXAMETHASONE IMPLANT MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL DEXAMETHASONE IMPLANT MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
  • TABLE 53. GLOBAL DEXAMETHASONE IMPLANT MARKET SIZE, BY ADULT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL DEXAMETHASONE IMPLANT MARKET SIZE, BY ADULT, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 55. GLOBAL DEXAMETHASONE IMPLANT MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL DEXAMETHASONE IMPLANT MARKET SIZE, BY GERIATRIC, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 57. GLOBAL DEXAMETHASONE IMPLANT MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL DEXAMETHASONE IMPLANT MARKET SIZE, BY PEDIATRIC, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 59. AMERICAS DEXAMETHASONE IMPLANT MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 60. AMERICAS DEXAMETHASONE IMPLANT MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
  • TABLE 61. AMERICAS DEXAMETHASONE IMPLANT MARKET SIZE, BY MACULAR EDEMA, 2018-2024 (USD MILLION)
  • TABLE 62. AMERICAS DEXAMETHASONE IMPLANT MARKET SIZE, BY MACULAR EDEMA, 2025-2030 (USD MILLION)
  • TABLE 63. AMERICAS DEXAMETHASONE IMPLANT MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 64. AMERICAS DEXAMETHASONE IMPLANT MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
  • TABLE 65. AMERICAS DEXAMETHASONE IMPLANT MARKET SIZE, BY MATERIAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 66. AMERICAS DEXAMETHASONE IMPLANT MARKET SIZE, BY MATERIAL TYPE, 2025-2030 (USD MILLION)
  • TABLE 67. AMERICAS DEXAMETHASONE IMPLANT MARKET SIZE, BY DELIVERY ROUTE, 2018-2024 (USD MILLION)
  • TABLE 68. AMERICAS DEXAMETHASONE IMPLANT MARKET SIZE, BY DELIVERY ROUTE, 2025-2030 (USD MILLION)
  • TABLE 69. AMERICAS DEXAMETHASONE IMPLANT MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 70. AMERICAS DEXAMETHASONE IMPLANT MARKET SIZE, BY END USERS, 2025-2030 (USD MILLION)
  • TABLE 71. AMERICAS DEXAMETHASONE IMPLANT MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 72. AMERICAS DEXAMETHASONE IMPLANT MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
  • TABLE 73. AMERICAS DEXAMETHASONE IMPLANT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. AMERICAS DEXAMETHASONE IMPLANT MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 75. UNITED STATES DEXAMETHASONE IMPLANT MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 76. UNITED STATES DEXAMETHASONE IMPLANT MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
  • TABLE 77. UNITED STATES DEXAMETHASONE IMPLANT MARKET SIZE, BY MACULAR EDEMA, 2018-2024 (USD MILLION)
  • TABLE 78. UNITED STATES DEXAMETHASONE IMPLANT MARKET SIZE, BY MACULAR EDEMA, 2025-2030 (USD MILLION)
  • TABLE 79. UNITED STATES DEXAMETHASONE IMPLANT MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 80. UNITED STATES DEXAMETHASONE IMPLANT MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
  • TABLE 81. UNITED STATES DEXAMETHASONE IMPLANT MARKET SIZE, BY MATERIAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 82. UNITED STATES DEXAMETHASONE IMPLANT MARKET SIZE, BY MATERIAL TYPE, 2025-2030 (USD MILLION)
  • TABLE 83. UNITED STATES DEXAMETHASONE IMPLANT MARKET SIZE, BY DELIVERY ROUTE, 2018-2024 (USD MILLION)
  • TABLE 84. UNITED STATES DEXAMETHASONE IMPLANT MARKET SIZE, BY DELIVERY ROUTE, 2025-2030 (USD MILLION)
  • TABLE 85. UNITED STATES DEXAMETHASONE IMPLANT MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 86. UNITED STATES DEXAMETHASONE IMPLANT MARKET SIZE, BY END USERS, 2025-2030 (USD MILLION)
  • TABLE 87. UNITED STATES DEXAMETHASONE IMPLANT MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 88. UNITED STATES DEXAMETHASONE IMPLANT MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
  • TABLE 89. UNITED STATES DEXAMETHASONE IMPLANT MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
  • TABLE 90. UNITED STATES DEXAMETHASONE IMPLANT MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
  • TABLE 91. CANADA DEXAMETHASONE IMPLANT MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 92. CANADA DEXAMETHASONE IMPLANT MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
  • TABLE 93. CANADA DEXAMETHASONE IMPLANT MARKET SIZE, BY MACULAR EDEMA, 2018-2024 (USD MILLION)
  • TABLE 94. CANADA DEXAMETHASONE IMPLANT MARKET SIZE, BY MACULAR EDEMA, 2025-2030 (USD MILLION)
  • TABLE 95. CANADA DEXAMETHASONE IMPLANT MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 96. CANADA DEXAMETHASONE IMPLANT MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
  • TABLE 97. CANADA DEXAMETHASONE IMPLANT MARKET SIZE, BY MATERIAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 98. CANADA DEXAMETHASONE IMPLANT MARKET SIZE, BY MATERIAL TYPE, 2025-2030 (USD MILLION)
  • TABLE 99. CANADA DEXAMETHASONE IMPLANT MARKET SIZE, BY DELIVERY ROUTE, 2018-2024 (USD MILLION)
  • TABLE 100. CANADA DEXAMETHASONE IMPLANT MARKET SIZE, BY DELIVERY ROUTE, 2025-2030 (USD MILLION)
  • TABLE 101. CANADA DEXAMETHASONE IMPLANT MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 102. CANADA DEXAMETHASONE IMPLANT MARKET SIZE, BY END USERS, 2025-2030 (USD MILLION)
  • TABLE 103. CANADA DEXAMETHASONE IMPLANT MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 104. CANADA DEXAMETHASONE IMPLANT MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
  • TABLE 105. MEXICO DEXAMETHASONE IMPLANT MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 106. MEXICO DEXAMETHASONE IMPLANT MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
  • TABLE 107. MEXICO DEXAMETHASONE IMPLANT MARKET SIZE, BY MACULAR EDEMA, 2018-2024 (USD MILLION)
  • TABLE 108. MEXICO DEXAMETHASONE IMPLANT MARKET SIZE, BY MACULAR EDEMA, 2025-2030 (USD MILLION)
  • TABLE 109. MEXICO DEXAMETHASONE IMPLANT MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 110. MEXICO DEXAMETHASONE IMPLANT MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
  • TABLE 111. MEXICO DEXAMETHASONE IMPLANT MARKET SIZE, BY MATERIAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 112. MEXICO DEXAMETHASONE IMPLANT MARKET SIZE, BY MATERIAL TYPE, 2025-2030 (USD MILLION)
  • TABLE 113. MEXICO DEXAMETHASONE IMPLANT MARKET SIZE, BY DELIVERY ROUTE, 2018-2024 (USD MILLION)
  • TABLE 114. MEXICO DEXAMETHASONE IMPLANT MARKET SIZE, BY DELIVERY ROUTE, 2025-2030 (USD MILLION)
  • TABLE 115. MEXICO DEXAMETHASONE IMPLANT MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 116. MEXICO DEXAMETHASONE IMPLANT MARKET SIZE, BY END USERS, 2025-2030 (USD MILLION)
  • TABLE 117. MEXICO DEXAMETHASONE IMPLANT MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 118. MEXICO DEXAMETHASONE IMPLANT MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
  • TABLE 119. BRAZIL DEXAMETHASONE IMPLANT MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 120. BRAZIL DEXAMETHASONE IMPLANT MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
  • TABLE 121. BRAZIL DEXAMETHASONE IMPLANT MARKET SIZE, BY MACULAR EDEMA, 2018-2024 (USD MILLION)
  • TABLE 122. BRAZIL DEXAMETHASONE IMPLANT MARKET SIZE, BY MACULAR EDEMA, 2025-2030 (USD MILLION)
  • TABLE 123. BRAZIL DEXAMETHASONE IMPLANT MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 124. BRAZIL DEXAMETHASONE IMPLANT MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
  • TABLE 125. BRAZIL DEXAMETHASONE IMPLANT MARKET SIZE, BY MATERIAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 126. BRAZIL DEXAMETHASONE IMPLANT MARKET SIZE, BY MATERIAL TYPE, 2025-2030 (USD MILLION)
  • TABLE 127. BRAZIL DEXAMETHASONE IMPLANT MARKET SIZE, BY DELIVERY ROUTE, 2018-2024 (USD MILLION)
  • TABLE 128. BRAZIL DEXAMETHASONE IMPLANT MARKET SIZE, BY DELIVERY ROUTE, 2025-2030 (USD MILLION)
  • TABLE 129. BRAZIL DEXAMETHASONE IMPLANT MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 130. BRAZIL DEXAMETHASONE IMPLANT MARKET SIZE, BY END USERS, 2025-2030 (USD MILLION)
  • TABLE 131. BRAZIL DEXAMETHASONE IMPLANT MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 132. BRAZIL DEXAMETHASONE IMPLANT MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
  • TABLE 133. ARGENTINA DEXAMETHASONE IMPLANT MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 134. ARGENTINA DEXAMETHASONE IMPLANT MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
  • TABLE 135. ARGENTINA DEXAMETHASONE IMPLANT MARKET SIZE, BY MACULAR EDEMA, 2018-2024 (USD MILLION)
  • TABLE 136. ARGENTINA DEXAMETHASONE IMPLANT MARKET SIZE, BY MACULAR EDEMA, 2025-2030 (USD MILLION)
  • TABLE 137. ARGENTINA DEXAMETHASONE IMPLANT MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 138. ARGENTINA DEXAMETHASONE IMPLANT MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
  • TABLE 139. ARGENTINA DEXAMETHASONE IMPLANT MARKET SIZE, BY MATERIAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 140. ARGENTINA DEXAMETHASONE IMPLANT MARKET SIZE, BY MATERIAL TYPE, 2025-2030 (USD MILLION)
  • TABLE 141. ARGENTINA DEXAMETHASONE IMPLANT MARKET SIZE, BY DELIVERY ROUTE, 2018-2024 (USD MILLION)
  • TABLE 142. ARGENTINA DEXAMETHASONE IMPLANT MARKET SIZE, BY DELIVERY ROUTE, 2025-2030 (USD MILLION)
  • TABLE 143. ARGENTINA DEXAMETHASONE IMPLANT MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 144. ARGENTINA DEXAMETHASONE IMPLANT MARKET SIZE, BY END USERS, 2025-2030 (USD MILLION)
  • TABLE 145. ARGENTINA DEXAMETHASONE IMPLANT MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 146. ARGENTINA DEXAMETHASONE IMPLANT MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
  • TABLE 147. EUROPE, MIDDLE EAST & AFRICA DEXAMETHASONE IMPLANT MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 148. EUROPE, MIDDLE EAST & AFRICA DEXAMETHASONE IMPLANT MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
  • TABLE 149. EUROPE, MIDDLE EAST & AFRICA DEXAMETHASONE IMPLANT MARKET SIZE, BY MACULAR EDEMA, 2018-2024 (USD MILLION)
  • TABLE 150. EUROPE, MIDDLE EAST & AFRICA DEXAMETHASONE IMPLANT MARKET SIZE, BY MACULAR EDEMA, 2025-2030 (USD MILLION)
  • TABLE 151. EUROPE, MIDDLE EAST & AFRICA DEXAMETHASONE IMPLANT MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 152. EUROPE, MIDDLE EAST & AFRICA DEXAMETHASONE IMPLANT MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
  • TABLE 153. EUROPE, MIDDLE EAST & AFRICA DEXAMETHASONE IMPLANT MARKET SIZE, BY MATERIAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 154. EUROPE, MIDDLE EAST & AFRICA DEXAMETHASONE IMPLANT MARKET SIZE, BY MATERIAL TYPE, 2025-2030 (USD MILLION)
  • TABLE 155. EUROPE, MIDDLE EAST & AFRICA DEXAMETHASONE IMPLANT MARKET SIZE, BY DELIVERY ROUTE, 2018-2024 (USD MILLION)
  • TABLE 156. EUROPE, MIDDLE EAST & AFRICA DEXAMETHASONE IMPLANT MARKET SIZE, BY DELIVERY ROUTE, 2025-2030 (USD MILLION)
  • TABLE 157. EUROPE, MIDDLE EAST & AFRICA DEXAMETHASONE IMPLANT MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 158. EUROPE, MIDDLE EAST & AFRICA DEXAMETHASONE IMPLANT MARKET SIZE, BY END USERS, 2025-2030 (USD MILLION)
  • TABLE 159. EUROPE, MIDDLE EAST & AFRICA DEXAMETHASONE IMPLANT MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 160. EUROPE, MIDDLE EAST & AFRICA DEXAMETHASONE IMPLANT MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
  • TABLE 161. EUROPE, MIDDLE EAST & AFRICA DEXAMETHASONE IMPLANT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 162. EUROPE, MIDDLE EAST & AFRICA DEXAMETHASONE IMPLANT MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 163. UNITED KINGDOM DEXAMETHASONE IMPLANT MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 164. UNITED KINGDOM DEXAMETHASONE IMPLANT MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
  • TABLE 165. UNITED KINGDOM DEXAMETHASONE IMPLANT MARKET SIZE, BY MACULAR EDEMA, 2018-2024 (USD MILLION)
  • TABLE 166. UNITED KINGDOM DEXAMETHASONE IMPLANT MARKET SIZE, BY MACULAR EDEMA, 2025-2030 (USD MILLION)
  • TABLE 167. UNITED KINGDOM DEXAMETHASONE IMPLANT MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 168. UNITED KINGDOM DEXAMETHASONE IMPLANT MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
  • TABLE 169. UNITED KINGDOM DEXAMETHASONE IMPLANT MARKET SIZE, BY MATERIAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 170. UNITED KINGDOM DEXAMETHASONE IMPLANT MARKET SIZE, BY MATERIAL TYPE, 2025-2030 (USD MILLION)
  • TABLE 171. UNITED KINGDOM DEXAMETHASONE IMPLANT MARKET SIZE, BY DELIVERY ROUTE, 2018-2024 (USD MILLION)
  • TABLE 172. UNITED KINGDOM DEXAMETHASONE IMPLANT MARKET SIZE, BY DELIVERY ROUTE, 2025-2030 (USD MILLION)
  • TABLE 173. UNITED KINGDOM DEXAMETHASONE IMPLANT MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 174. UNITED KINGDOM DEXAMETHASONE IMPLANT MARKET SIZE, BY END USERS, 2025-2030 (USD MILLION)
  • TABLE 175. UNITED KINGDOM DEXAMETHASONE IMPLANT MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 176. UNITED KINGDOM DEXAMETHASONE IMPLANT MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
  • TABLE 177. GERMANY DEXAMETHASONE IMPLANT MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 178. GERMANY DEXAMETHASONE IMPLANT MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
  • TABLE 179. GERMANY DEXAMETHASONE IMPLANT MARKET SIZE, BY MACULAR EDEMA, 2018-2024 (USD MILLION)
  • TABLE 180. GERMANY DEXAMETHASONE IMPLANT MARKET SIZE, BY MACULAR EDEMA, 2025-2030 (USD MILLION)
  • TABLE 181. GERMANY DEXAMETHASONE IMPLANT MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 182. GERMANY DEXAMETHASONE IMPLANT MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
  • TABLE 183. GERMANY DEXAMETHASONE IMPLANT MARKET SIZE, BY MATERIAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 184. GERMANY DEXAMETHASONE IMPLANT MARKET SIZE, BY MATERIAL TYPE, 2025-2030 (USD MILLION)
  • TABLE 185. GERMANY DEXAMETHASONE IMPLANT MARKET SIZE, BY DELIVERY ROUTE, 2018-2024 (USD MILLION)
  • TABLE 186. GERMANY DEXAMETHASONE IMPLANT MARKET SIZE, BY DELIVERY ROUTE, 2025-2030 (USD MILLION)
  • TABLE 187. GERMANY DEXAMETHASONE IMPLANT MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 188. GERMANY DEXAMETHASONE IMPLANT MARKET SIZE, BY END USERS, 2025-2030 (USD MILLION)
  • TABLE 189. GERMANY DEXAMETHASONE IMPLANT MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 190. GERMANY DEXAMETHASONE IMPLANT MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
  • TABLE 191. FRANCE DEXAMETHASONE IMPLANT MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 192. FRANCE DEXAMETHASONE IMPLANT MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
  • TABLE 193. FRANCE DEXAMETHASONE IMPLANT MARKET SIZE, BY MACULAR EDEMA, 2018-2024 (USD MILLION)
  • TABLE 194. FRANCE DEXAMETHASONE IMPLANT MARKET SIZE, BY MACULAR EDEMA, 2025-2030 (USD MILLION)
  • TABLE 195. FRANCE DEXAMETHASONE IMPLANT MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 196. FRANCE DEXAMETHASONE IMPLANT MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
  • TABLE 197. FRANCE DEXAMETHASONE IMPLANT MARKET SIZE, BY MATERIAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 198. FRANCE DEXAMETHASONE IMPLANT MARKET SIZE, BY MATERIAL TYPE, 2025-2030 (USD MILLION)
  • TABLE 199. FRANCE DEXAMETHASONE IMPLANT MARKET SIZE, BY DELIVERY ROUTE, 2018-2024 (USD MILLION)
  • TABLE 200. FRANCE DEXAMETHASONE IMPLANT MARKET SIZE, BY DELIVERY ROUTE, 2025-2030 (USD MILLION)
  • TABLE 201. FRANCE DEXAMETHASONE IMPLANT MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 202. FRANCE DEXAMETHASONE IMPLANT MARKET SIZE, BY END USERS, 2025-2030 (USD MILLION)
  • TABLE 203. FRANCE DEXAMETHASONE IMPLANT MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 204. FRANCE DEXAMETHASONE IMPLANT MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
  • TABLE 205. RUSSIA DEXAMETHASONE IMPLANT MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 206. RUSSIA DEXAMETHASONE IMPLANT MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
  • TABLE 207. RUSSIA DEXAMETHASONE IMPLANT MARKET SIZE, BY MACULAR EDEMA, 2018-2024 (USD MILLION)
  • TABLE 208. RUSSIA DEXAMETHASONE IMPLANT MARKET SIZE, BY MACULAR EDEMA, 2025-2030 (USD MILLION)
  • TABLE 209. RUSSIA DEXAMETHASONE IMPLANT MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 210. RUSSIA DEXAMETHASONE IMPLANT MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
  • TABLE 211. RUSSIA DEXAMETHASONE IMPLANT MARKET SIZE, BY MATERIAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 212. RUSSIA DEXAMETHASONE IMPLANT MARKET SIZE, BY MATERIAL TYPE, 2025-2030 (USD MILLION)
  • TABLE 213. RUSSIA DEXAMETHASONE IMPLANT MARKET SIZE, BY DELIVERY ROUTE, 2018-2024 (USD MILLION)
  • TABLE 214. RUSSIA DEXAMETHASONE IMPLANT MARKET SIZE, BY DELIVERY ROUTE, 2025-2030 (USD MILLION)
  • TABLE 215. RUSSIA DEXAMETHASONE IMPLANT MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 216. RUSSIA DEXAMETHASONE IMPLANT MARKET SIZE, BY END USERS, 2025-2030 (USD MILLION)
  • TABLE 217. RUSSIA DEXAMETHASONE IMPLANT MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 218. RUSSIA DEXAMETHASONE IMPLANT MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
  • TABLE 219. ITALY DEXAMETHASONE IMPLANT MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 220. ITALY DEXAMETHASONE IMPLANT MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
  • TABLE 221. ITALY DEXAMETHASONE IMPLANT MARKET SIZE, BY MACULAR EDEMA, 2018-2024 (USD MILLION)
  • TABLE 222. ITALY DEXAMETHASONE IMPLANT MARKET SIZE, BY MACULAR EDEMA, 2025-2030 (USD MILLION)
  • TABLE 223. ITALY DEXAMETHASONE IMPLANT MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 224. ITALY DEXAMETHASONE IMPLANT MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
  • TABLE 225. ITALY DEXAMETHASONE IMPLANT MARKET SIZE, BY MATERIAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 226. ITALY DEXAMETHASONE IMPLANT MARKET SIZE, BY MATERIAL TYPE, 2025-2030 (USD MILLION)
  • TABLE 227. ITALY DEXAMETHASONE IMPLANT MARKET SIZE, BY DELIVERY ROUTE, 2018-2024 (USD MILLION)
  • TABLE 228. ITALY DEXAMETHASONE IMPLANT MARKET SIZE, BY DELIVERY ROUTE, 2025-2030 (USD MILLION)
  • TABLE 229. ITALY DEXAMETHASONE IMPLANT MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 230. ITALY DEXAMETHASONE IMPLANT MARKET SIZE, BY END USERS, 2025-2030 (USD MILLION)
  • TABLE 231. ITALY DEXAMETHASONE IMPLANT MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 232. ITALY DEXAMETHASONE IMPLANT MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
  • TABLE 233. SPAIN DEXAMETHASONE IMPLANT MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 234. SPAIN DEXAMETHASONE IMPLANT MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
  • TABLE 235. SPAIN DEXAMETHASONE IMPLANT MARKET SIZE, BY MACULAR EDEMA, 2018-2024 (USD MILLION)
  • TABLE 236. SPAIN DEXAMETHASONE IMPLANT MARKET SIZE, BY MACULAR EDEMA, 2025-2030 (USD MILLION)
  • TABLE 237. SPAIN DEXAMETHASONE IMPLANT MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 238. SPAIN DEXAMETHASONE IMPLANT MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
  • TABLE 239. SPAIN DEXAMETHASONE IMPLANT MARKET SIZE, BY MATERIAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 240. SPAIN DEXAMETHASONE IMPLANT MARKET SIZE, BY MATERIAL TYPE, 2025-2030 (USD MILLION)
  • TABLE 241. SPAIN DEXAMETHASONE IMPLANT MARKET SIZE, BY DELIVERY ROUTE, 2018-2024 (USD MILLION)
  • TABLE 242. SPAIN DEXAMETHASONE IMPLANT MARKET SIZE, BY DELIVERY ROUTE, 2025-2030 (USD MILLION)
  • TABLE 243. SPAIN DEXAMETHASONE IMPLANT MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 244. SPAIN DEXAMETHASONE IMPLANT MARKET SIZE, BY END USERS, 2025-2030 (USD MILLION)
  • TABLE 245. SPAIN DEXAMETHASONE IMPLANT MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 246. SPAIN DEXAMETHASONE IMPLANT MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
  • TABLE 247. UNITED ARAB EMIRATES DEXAMETHASONE IMPLANT MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 248. UNITED ARAB EMIRATES DEXAMETHASONE IMPLANT MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
  • TABLE 249. UNITED ARAB EMIRATES DEXAMETHASONE IMPLANT MARKET SIZE, BY MACULAR EDEMA, 2018-2024 (USD MILLION)
  • TABLE 250. UNITED ARAB EMIRATES DEXAMETHASONE IMPLANT MARKET SIZE, BY MACULAR EDEMA, 2025-2030 (USD MILLION)
  • TABLE 251. UNITED ARAB EMIRATES DEXAMETHASONE IMPLANT MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 252. UNITED ARAB EMIRATES DEXAMETHASONE IMPLANT MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
  • TABLE 253. UNITED ARAB EMIRATES DEXAMETHASONE IMPLANT MARKET SIZE, BY MATERIAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 254. UNITED ARAB EMIRATES DEXAMETHASONE IMPLANT MARKET SIZE, BY MATERIAL TYPE, 2025-2030 (USD MILLION)
  • TABLE 255. UNITED ARAB EMIRATES DEXAMETHASONE IMPLANT MARKET SIZE, BY DELIVERY ROUTE, 2018-2024 (USD MILLION)
  • TABLE 256. UNITED ARAB EMIRATES DEXAMETHASONE IMPLANT MARKET SIZE, BY DELIVERY ROUTE, 2025-2030 (USD MILLION)
  • TABLE 257. UNITED ARAB EMIRATES DEXAMETHASONE IMPLANT MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 258. UNITED ARAB EMIRATES DEXAMETHASONE IMPLANT MARKET SIZE, BY END USERS, 2025-2030 (USD MILLION)
  • TABLE 259. UNITED ARAB EMIRATES DEXAMETHASONE IMPLANT MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 260. UNITED ARAB EMIRATES DEXAMETHASONE IMPLANT MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
  • TABLE 261. SAUDI ARABIA DEXAMETHASONE IMPLANT MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 262. SAUDI ARABIA DEXAMETHASONE IMPLANT MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
  • TABLE 263. SAUDI ARABIA DEXAMETHASONE IMPLANT MARKET SIZE, BY MACULAR EDEMA, 2018-2024 (USD MILLION)
  • TABLE 264. SAUDI ARABIA DEXAMETHASONE IMPLANT MARKET SIZE, BY MACULAR EDEMA, 2025-2030 (USD MILLION)
  • TABLE 265. SAUDI ARABIA DEXAMETHASONE IMPLANT MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 266. SAUDI ARABIA DEXAMETHASONE IMPLANT MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
  • TABLE 267. SAUDI ARABIA DEXAMETHASONE IMPLANT MARKET SIZE, BY MATERIAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 268. SAUDI ARABIA DEXAMETHASONE IMPLANT MARKET SIZE, BY MATERIAL TYPE, 2025-2030 (USD MILLION)
  • TABLE 269. SAUDI ARABIA DEXAMETHASONE IMPLANT MARKET SIZE, BY DELIVERY ROUTE, 2018-2024 (USD MILLION)
  • TABLE 270. SAUDI ARABIA DEXAMETHASONE IMPLANT MARKET SIZE, BY DELIVERY ROUTE, 2025-2030 (USD MILLION)
  • TABLE 271. SAUDI ARABIA DEXAMETHASONE IMPLANT MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 272. SAUDI ARABIA DEXAMETHASONE IMPLANT MARKET SIZE, BY END USERS, 2025-2030 (USD MILLION)
  • TABLE 273. SAUDI ARABIA DEXAMETHASONE IMPLANT MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 274. SAUDI ARABIA DEXAMETHASONE IMPLANT MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
  • TABLE 275. SOUTH AFRICA DEXAMETHASONE IMPLANT MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 276. SOUTH AFRICA DEXAMETHASONE IMPLANT MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
  • TABLE 277. SOUTH AFRICA DEXAMETHASONE IMPLANT MARKET SIZE, BY MACULAR EDEMA, 2018-2024 (USD MILLION)
  • TABLE 278. SOUTH AFRICA DEXAMETHASONE IMPLANT MARKET SIZE, BY MACULAR EDEMA, 2025-2030 (USD MILLION)
  • TABLE 279. SOUTH AFRICA DEXAMETHASONE IMPLANT MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 280. SOUTH AFRICA DEXAMETHASONE IMPLANT MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
  • TABLE 281. SOUTH AFRICA DEXAMETHASONE IMPLANT MARKET SIZE, BY MATERIAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 282. SOUTH AFRICA DEXAMETHASONE IMPLANT MARKET SIZE, BY MATERIAL TYPE, 2025-2030 (USD MILLION)
  • TABLE 283. SOUTH AFRICA DEXAMETHASONE IMPLANT MARKET SIZE, BY DELIVERY ROUTE, 2018-2024 (USD MILLION)
  • TABLE 284. SOUTH AFRICA DEXAMETHASONE IMPLANT MARKET SIZE, BY DELIVERY ROUTE, 2025-2030 (USD MILLION)
  • TABLE 285. SOUTH AFRICA DEXAMETHASONE IMPLANT MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 286. SOUTH AFRICA DEXAMETHASONE IMPLANT MARKET SIZE, BY END USERS, 2025-2030 (USD MILLION)
  • TABLE 287. SOUTH AFRICA DEXAMETHASONE IMPLANT MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 288. SOUTH AFRICA DEXAMETHASONE IMPLANT MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
  • TABLE 289. DENMARK DEXAMETHASONE IMPLANT MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 290. DENMARK DEXAMETHASONE IMPLANT MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
  • TABLE 291. DENMARK DEXAMETHASONE IMPLANT MARKET SIZE, BY MACULAR EDEMA, 2018-2024 (USD MILLION)
  • TABLE 292. DENMARK DEXAMETHASONE IMPLANT MARKET SIZE, BY MACULAR EDEMA, 2025-2030 (USD MILLION)
  • TABLE 293. DENMARK DEXAMETHASONE IMPLANT MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 294. DENMARK DEXAMETHASONE IMPLANT MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
  • TABLE 295. DENMARK DEXAMETHASONE IMPLANT MARKET SIZE, BY MATERIAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 296. DENMARK DEXAMETHASONE IMPLANT MARKET SIZE, BY MATERIAL TYPE, 2025-2030 (USD MILLION)
  • TABLE 297. DENMARK DEXAMETHASONE IMPLANT MARKET SIZE, BY DELIVERY ROUTE, 2018-2024 (USD MILLION)
  • TABLE 298. DENMARK DEXAMETHASONE IMPLANT MARKET SIZE, BY DELIVERY ROUTE, 2025-2030 (USD MILLION)
  • TABLE 299. DENMARK DEXAMETHASONE IMPLANT MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 300. DENMARK DEXAMETHASONE IMPLANT MARKET SIZE, BY END USERS, 2025-2030 (USD MILLION)
  • TABLE 301. DENMARK DEXAMETHASONE IMPLANT MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 302. DENMARK DEXAMETHASONE IMPLANT MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
  • TABLE 303. NETHERLANDS DEXAMETHASONE IMPLANT MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 304. NETHERLANDS DEXAMETHASONE IMPLANT MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
  • TABLE 305. NETHERLANDS DEXAMETHASONE IMPLANT MARKET SIZE, BY MACULAR EDEMA, 2018-2024 (USD MILLION)
  • TABLE 306. NETHERLANDS DEXAMETHASONE IMPLANT MARKET SIZE, BY MACULAR EDEMA, 2025-2030 (USD MILLION)
  • TABLE 307. NETHERLANDS DEXAMETHASONE IMPLANT MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 308. NETHERLANDS DEXAMETHASONE IMPLANT MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
  • TABLE 309. NETHERLANDS DEXAMETHASONE IMPLANT MARKET SIZE, BY MATERIAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 310. NETHERLANDS DEXAMETHASONE IMPLANT MARKET SIZE, BY MATERIAL TYPE, 2025-2030 (USD MILLION)
  • TABLE 311. NETHERLANDS DEXAMETHASONE IMPLANT MARKET SIZE, BY DELIVERY ROUTE, 2018-2024 (USD MILLION)
  • TABLE 312. NETHERLANDS DEXAMETHASONE IMPLANT MARKET SIZE, BY DELIVERY ROUTE, 2025-2030 (USD MILLION)
  • TABLE 313. NETHERLANDS DEXAMETHASONE IMPLANT MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 314. NETHERLANDS DEXAMETHASONE IMPLANT MARKET SIZE, BY END USERS, 2025-2030 (USD MILLION)
  • TABLE 315. NETHERLANDS DEXAMETHASONE IMPLANT MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 316. NETHERLANDS DEXAMETHASONE IMPLANT MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
  • TABLE 317. QATAR DEXAMETHASONE IMPLANT MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 318. QATAR DEXAMETHASONE IMPLANT MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
  • TABLE 319. QATAR DEXAMETHASONE IMPLANT MARKET SIZE, BY MACULAR EDEMA, 2018-2024 (USD MILLION)
  • TABLE 320. QATAR DEXAMETHASONE IMPLANT MARKET SIZE, BY MACULAR EDEMA, 2025-2030 (USD MILLION)
  • TABLE 321. QATAR DEXAMETHASONE IMPLANT MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 322. QATAR DEXAMETHASONE IMPLANT MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
  • TABLE 323. QATAR DEXAMETHASONE IMPLANT MARKET SIZE, BY MATERIAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 324. QATAR DEXAMETHASONE IMPLANT MARKET SIZE, BY MATERIAL TYPE, 2025-2030 (USD MILLION)
  • TABLE 325. QATAR DEXAMETHASONE IMPLANT MARKET SIZE, BY DELIVERY ROUTE, 2018-2024 (USD MILLION)
  • TABLE 326. QATAR DEXAMETHASONE IMPLANT MARKET SIZE, BY DELIVERY ROUTE, 2025-2030 (USD MILLION)
  • TABLE 327. QATAR DEXAMETHASONE IMPLANT MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 328. QATAR DEXAMETHASONE IMPLANT MARKET SIZE, BY END USERS, 2025-2030 (USD MILLION)
  • TABLE 329. QATAR DEXAMETHASONE IMPLANT MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 330. QATAR DEXAMETHASONE IMPLANT MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
  • TABLE 331. FINLAND DEXAMETHASONE IMPLANT MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 332. FINLAND DEXAMETHASONE IMPLANT MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
  • TABLE 333. FINLAND DEXAMETHASONE IMPLANT MARKET SIZE, BY MACULAR EDEMA, 2018-2024 (USD MILLION)
  • TABLE 334. FINLAND DEXAMETHASONE IMPLANT MARKET SIZE, BY MACULAR EDEMA, 2025-2030 (USD MILLI